Conclusions
This guideline is the second in a row of three grouped guidelines by ESCMID and others for the diagnosis and management of fungal diseases. Other groups are now adopting the ESCMID strength of recommendation and quality of evidence as well (ESCMID Study Group for Clostridium difficile [ 17], and ESCMID Study Group for Biofilms). This guideline serves as guidance in the clinical care of patients in Europe and potentially worldwide. Although guidelines are helpful tools for everyday decision-making, a clinical judgement call for the individual patient remains the main fundamental requirement for the physician in charge.